A drug regimen containing Isentress (raltegravir), Intelence (etravirine) and Norvir (ritonavir)?boosted Prezista (darunavir) has been shown to be “highly potent and durable in terms of efficacy and safety” in a French clinical trial involving heavily treatment-experienced people living with HIV. According to the research paper published ahead of print by the Journal of Acquired Immune Deficiency Syndromes (JAIDS), 88 percent of those using this regimen had undetectable viral loads after nearly two years of treatment.
↧